Skip to Main Content

1,619

Views

2

CrossRef citations to date

0

Altmetric

Original Article

Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study

Per M. Hellströma Department of Medical Sciences, Uppsala University, Uppsala, SwedenCorrespondence[email protected]

https://orcid.org/0000-0001-8428-0772 View further author information

,

Eric Gemmenb Epidemiology & Outcomes Research, IQVIA Real World Solutions, Cambridge, MA, USAView further author information

,

Heather A. Wardb Epidemiology & Outcomes Research, IQVIA Real World Solutions, Cambridge, MA, USAView further author information

,

Hyewon Kooc Global Database Studies, Real World Solutions, IQVIA Solutions AB, Arenastaden, SwedenView further author information

,

Freddy Faccind GMA Biotherapeutics, AbbVie Inc, San Juan, Puerto RicoView further author information

,

Zhenyi Xuee Global Medical Affairs Statistics, Data and Statistical Sciences, AbbVie Inc, North Chicago, IL, USAView further author information

&

Petter Malmborgf Department of Clinical Science and Education, Karolinska Institute, Stockholm, SwedenView further author information